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Abstract
Background: Vitamin D deficiency is associated with heightened risk of cardiovascular disease.
Potential mechanisms include involvement of vitamin D in regulation of renin-angiotensin system
and manufacture and secretion of cardiac natriuretic peptides. Our aim was to document
relationships between 25 hydroxyvitamin [25(OH)D] and N-terminal pro B-type natriuretic
peptide (NT-proBNP) and plasma renin activity (PRA) levels and to document the effect of vitamin
D administration on NT-proBNP and PRA levels in vitamin D deficient subjects.
Methods: Serum 25(OH)D, parathyroid hormone (PTH), plasma or serum NT-proBNP and PRA
levels were measured at baseline in nulliparous and lactating women and after 2 months of oral
vitamin D2 (2,000 IU/day or 60,000 IU/month) supplementation to lactating women.
Results: Baseline levels of 25(OH)D were low (<50 nmol/L) in most women whereas PRA and
NT-proBNP levels were within the normal range. There were no significant correlations between
baseline 25(OH)D or PTH with NT-proBNP and PRA. Vitamin D administration over a 2-month
period in lactating women was associated with a decline in NT-proBNP (by 9.1 ± 2.0 pmol/L; p <
0.001) and PRA (by 0.32 ± 0.17 nmol/L/hr; p = 0.064). However, there were no significant
correlations between the changes from baseline in 25(OH)D and either NT-proBNP (r = -0.04, p
= 0.8) or PRA (r = -0.04, p = 0.8).
Conclusion: We found no significant correlations between 25(OH)D or PTH with NT-proBNP
and PRA in vitamin D deficient women. Further information is required to clarify the effects of
vitamin D administration on cardiac structure and function.
Background
In addition to metabolic bone disease, new evidence links
vitamin D deficiency with many disease states including
autoimmune diseases, multiple sclerosis, some forms of
cancer (breast, ovarian, colon), metabolic syndrome and
type 2 diabetes [1-3]. More recently, vitamin D deficiency
has been linked with heightened risk of hypertension and
cardiovascular disease [4-8]. Potential mechanisms that
may explain this link include involvement of vitamin D in
the regulation of the renin-angiotensin system [9-11], and
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the negative vascular effects of secondary hyperparathy-
roidism [12]. In addition, activation of nuclear vitamin D
receptors present in the myocardium can inhibit cardiac
growth and hypertrophy whilst also suppressing the man-
ufacture and secretion of the cardiac natriuretic peptides
in both atrial and ventricular myocytes [13].
In some Arab countries, vitamin D deficiency is particu-
larly common especially amongst women [14,15], and it
has been proposed that correction of low vitamin D status
in such a cohort might reduce the incidence of cardiovas-
cular disease, especially heart failure [16]. Circulating lev-
els of B-type natriuretic peptide (BNP) and the 1–76
amino-terminal fragment of pro-BNP (NT-proBNP) are
elevated in acute and chronic cardiac impairment in pro-
portion to the degree of hemodynamic compromise
[17,18]. NT-proBNP rises more steeply than pro-BNP as
cardiac function deteriorates and may be a more sensitive
marker of cardiac dysfunction [18]. It was recently dem-
onstrated that both BNP and NT-proBNP correlated
inversely with 25 hydroxyvitamin D [25(OH)D] concen-
trations (rs = -0.60, p = 0.007 and rs = -0.64, p = 0.003,
respectively) in patients on maintenance peritoneal dialy-
sis [19].
The objectives of the present study were to document rela-
tionships between plasma levels of NT-proBNP and
serum 25(OH)D concentrations and to document the
effect of vitamin D administration on NT-proBNP and
plasma renin activity (PRA) levels in vitamin D deficient
subjects.
Methods
The study protocol was approved by the human research
ethics committee of the Al Ain Medical District and sub-
jects received both oral and written information and gave
informed consent. We recruited 88 generally healthy nul-
liparous Emirati women in the reproductive age group,
many of whom were medical students and interns work-
ing at Tawam hospital in Al Ain city, and 90 lactating
women (15 UAE, 61 other Arab, and 14 South Asian) at
the time of their first postnatal visit to the Maternal and
Child Health center in Al Ain city (latitude 24°N and lon-
gitude 55°E) [14]. Lactating women were eligible if they
planned to continue breast-feeding for the next 3 months.
Exclusion criteria included pregnancy, history of meta-
bolic bone disease or calcium disorders and treatment
with vitamin D (other than multivitamins) within the
past 1 year. Enrolment began in September 2005 and fin-
ished in February 2006.
This was an open label randomized parallel group clinical
trial of lactating and nulliparous women [14]. Consenting
subjects in each group were randomly allocated to either
2000 IU daily dose or 60,000 IU monthly dose of vitamin
D2 in a 1:1 ratio within permuted blocks of size 10. Of the
88 nulliparous women enrolled initially, 55 completed 1
month, 27 completed 2 months and 23 completed the 3-
month study period. Most subjects who withdrew from
the study were contacted and none specified any particu-
lar reason for withdrawal. Sufficient follow-up serum
samples were also not available except for very few sub-
jects. We therefore measured NT-proBNP only in baseline
samples from subjects with sufficient stored serum (n =
53) using an electrochemiluminescence immunoassay
(Roche Elecsys 1010/2010 system). Intra-assay variability
was <1.5%.
Of the 90 lactating women enrolled initially, 69 com-
pleted 1 month, 58 completed 2 months and 48 com-
pleted the 3-month study period. There were no
significant differences in baseline characteristics between
women who completed the study and those who dropped
out. Venous samples drawn at baseline (21 ± 3.4 days,
mean ± SEM, post partum) and monthly thereafter
showed peak levels of 25(OH)D at 2 months [14]. We
therefore measured NT-proBNP and PRA in baseline and
2 month samples from subjects with sufficient stored
plasma (n = 53 subjects for PRA and n = 46 subjects for
NT-proBNP). Original samples were taken into chilled
tubes containing EDTA and centrifuged at +4°C and the
plasma stored at -80°C. One aliquot of plasma from each
subject was couriered on dry ice to the Endolab in
Christchurch, New Zealand where NT-proBNP and PRA
were measured in single assay runs to avoid inter-assay
variability [18]. Intra-assay variability varied between
3.7% for PRA and 6.7% for NT-proBNP. Reference ranges
were NT-proBNP 2–50 pmol/L, and PRA 0.4–2.3 nmol/L/
hr. Serum calcium was measured with Beckman Synchron
autoanalyzer. Serum 25(OH)D concentrations were
determined by a radioimmunoassay that measures both
25(OH)D2 and 25(OH)D3 equally (DiaSorin; Stillwater,
Minnesota). The intra- and inter-assay coefficients of var-
iation (CVs) were 8.3% and 3.2%, respectively. Serum
25(OH)D concentration <50 nmol/L (20 ng/ml) was con-
sidered to reflect vitamin D deficiency based on studies in
the literature (19, 25). Serum intact parathyroid hormone
(PTH) was measured by immunoradiometric assay (Diag-
nostic Products Corporation; Los Angeles, California).
The intra- and inter-assay coefficients of variation (CVs)
were 6% and 5.1%, respectively.
Data were analysed with SPSS statistical software (version
15; SPSS Inc, Chicago). Data are shown as mean ± SEM
unless mentioned otherwise. Differences between groups
were assessed by two-tailed t-tests for continuous varia-
bles and by chi-square tests for categorical variables.
Paired observations were analysed using paired two-tailed
t-tests. Correlations between different variables wereBMC Endocrine Disorders 2009, 9:4 http://www.biomedcentral.com/1472-6823/9/4
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examined using Spearman's correlation coefficients. P-
values < 0.05 were considered significant.
Results
Baseline data
The baseline characteristics of nulliparous and lactating
women are shown in Table 1. Subjects were generally
healthy and none suffered from diabetes mellitus, hyper-
tension or heart disease. Baseline serum concentrations of
25(OH)D were low (<50 nmol/L) in all subjects except in
one nulliparous and one lactating woman and they corre-
lated negatively with PTH (r = -0.1, p = 0.6 in nulliparous
women and r = -0.5, p < 0.001 in lactating women). In
nulliparous women, NT-proBNP values were undetecta-
ble in more than half (51%) of the subjects. In lactating
women, NT-proBNP levels were within the normal range
(Table 2) but they dropped significantly with increasing
postpartum days until they reached a plateau at ~14 days
postpartum (Fig 1). There were no statistically significant
correlations between NT-proBNP and either 25(OH)D (r
= 0.01, p = 0.9) or PTH (r = -0.1, p = 0.4) in nulliparous
women. There were also no statistically significant corre-
lations between 25(OH)D and either NT-proBNP (r =
0.003, p = 1.0) or PRA (r = -0.1, p = 0.5) or between PTH
and either NT-proBNP (r = 0.1, p = 0.5) or PRA (r = -0.1,
p = 0.4) in lactating women.
Follow-up data
Of the 58 lactating women who completed 2 months of
the study, sufficient stored plasma was available in 53
subjects. Twenty-six women were allocated to the daily
and 27 were allocated to the monthly regimen. No signif-
icant differences in baseline characteristics were found
among subjects based on the allocated regimen or availa-
bility of sufficient stored samples (data not shown). As
expected, mean concentration of 25(OH)D increased sig-
nificantly (p < 0.001) over the 2 month period of vitamin
D supplementation from 26.6 ± 1.5 to 39.0 ± 1.7 nmol/L
(Table 3). Similarly, mean serum PTH concentration
decreased but not statistically significantly (Table 3). Over
the same time period, plasma levels of NT-proBNP
declined in 33 of 46 women, and overall substantially (by
26%) and significantly (p < 0.001) by 9.1 ± 2.0 pmol/L
whilst PRA fell in 32 of 53 women, but overall only
slightly (by 0.32 ± 0.17 nmol/L/hr) and not statistically
significantly (p = 0.064). The above changes were not sig-
nificantly different between the daily and intermittent
supplementation regimen groups (Table 3). Overall, there
were no significant changes in mean serum calcium con-
centrations, blood pressure, and weight. There were no
significant correlations between the changes from base-
line in 25(OH)D and NT-proBNP (r = -0.04, p = 0.8)
whether the baseline sample was drawn <14 or ≥ 14 days
postpartum (r = -0.3, p = 0.2 and r = 0.1, p = 0.6; respec-
tively) (Fig 2). In the 10 (18.9%) women who achieved
25(OH)D concentrations of ≥ 50 nmol/L at 2 months, the
changes from baseline in 25(OH)D and NT-proBNP also
showed no significant correlation (r = 0.5, p = 0.2). There
were also no significant correlations between the changes
from baseline in 25(OH)D and PRA (r = -0.04, p = 0.8) or
between the changes from baseline in PTH and either NT-
proBNP (r = -0.02, p = 0.9) or PRA (r = -0.1; p = 0.5).
Table 1: Baseline characteristics of study subjects
Characteristic Nulliparous Lactating
n = 63 n = 53
Ethnicity1
UAE (%) 98.4 [62] 15.1 [8]
Other Arab (%) 1.6 [1] 67.9 [36]
South Asian (%) 0 [0] 17.0 [9]
Age (y)2 24.0 ± 0.6 29.8 ± 0.9
Weight (kg)2 63.7 ± 2.9 72.2 ± 1.7
BMI (kg/m2)2 24.2 ± 0.7 28.4 ± 0.6
Systolic Bp (mm Hg)2 108 ± 1 120 ± 1
Diastolic Bp (mm Hg)2 70 ± 1 76 ± 1
Parity3 03 . 0
Health3,4 11
Sunlight exposure (min/day)2 5.6 ± 1.8 0.8 ± 0.5
Multivitamin use (%)1 3.2 [2] 49 [26]
Vitamin D intake (mcg/day)2 3.7 ± 0.3 4.5 ± 0.4
Calcium intake (g/day)2 0.5 ± 0.05 0.6 ± 0.05
1 n in brackets;
2 Mean ± SEM;
3 Median;
4 Self reported general health status (1–5): excellent, very good, good, fair, poor.BMC Endocrine Disorders 2009, 9:4 http://www.biomedcentral.com/1472-6823/9/4
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Table 2: Baseline biochemical variables in nulliparous and lactating women1
Group Nulliparous women (n = 63) Lactating women (n = 53)
Serum 25OHD (nmol/L) 19.0 ± 1.4 26.6 ± 1.4
Serum PTH (pmol/L) 7.3 ± 0.4 4.6 ± 0.4
Serum calcium (mmol/L) 2.3 ± 0.01 2.4 ± 0.01
NTproBNp (pmol/L) 1.6 ± 0.3 19.2 ± 2.2
PRA (nmol/L/hr) ----- 2.0 ± 0.1
1 Mean ± SEM;
25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; NT-proBNP, N-terminal pro B-type natriuretic peptide; PRA, plasma renin activity.
Discussion
Vitamin D deficiency may adversely affect cardiac func-
tion [6-8,20] and vitamin D administration under these
conditions may be beneficial [21]. Park and colleagues
reported that calcitriol, administered intravenously twice
weekly over 15 weeks, reduced left ventricular mass and
suppressed circulating levels of renin, angiotensin II and
ANP in patients on chronic hemodialysis with secondary
hyperparathyroidism [22]. Similar findings of regression
of cardiac hypertrophy (together with reduced QT disper-
sion) during calcitriol administration in a similar cohort
of patients were reported subsequently by the same group
[23]. Other investigators also found that vitamin D
administration for patients with congestive heart failure
improved pro-inflammatory and anti-inflammatory
cytokine levels but there was no significant decline in NT-
proBNP levels [21]. Our results show no significant corre-
lations between baseline 25(OH)D concentrations and
NT-proBNP levels in vitamin D deficient nulliparous
women or between baseline 25(OH)D concentrations
and NT-proBNP and PRA in vitamin D deficient lactating
women. Although vitamin D administration over a 2-
month period in lactating women was associated with a
statistically significant decline in NT-proBNP levels and a
non-statistically significant decline in PRA, there were no
significant correlations between the change from baseline
in 25(OH)D concentrations or PTH with the change from
baseline in NT-proBNP and PRA levels. This suggests that
the decline we observed in NT-proBNP is unlikely related
to vitamin D administration but is probably related to
other factors such as postpartum blood volume changes.
Pregnancy represents a state of physiologic volume expan-
sion as maternal blood volume increases ~40%–45%
above non-pregnancy volumes [24]. By 1 week after deliv-
ery, the blood volume returns nearly to its non-pregnancy
value [25]. NT-proBNP levels, on the other hand, increase
by 2-fold within the first 28 hours after delivery suggesting
a role in postpartum diuresis [26]. Our results suggest that
NT-proBNP levels drop quickly thereafter until they reach
a plateau at ~14 days postpartum.
Our data also confirm previous studies showing a high
prevalence of severe vitamin D deficiency among women
in the Middle East due to sunshine deprivation and inad-
equate vitamin D intake [14,15,27]. Our current study did
not evaluate seasonal changes in serum 25(OH)D concen-
trations but our previous studies showed no significant
seasonal variation in 25(OH)D concentrations between
September and February in the UAE, where there is abun-
dant sunshine year-round [15]. In addition, vitamin D
fortification of food is not mandatory in many Middle
Eastern countries, and the current dietary intake of vita-
min D is relatively low [15]. Vitamin D2 supplementation
with 2000 IU daily or 60,000 IU monthly for 2 months in
this study increased serum 25(OH)D concentrations sig-
nificantly but these concentrations reached an acceptable
level (≥ 50 nmol/L) in only a small proportion of studied
women [14]. Although the mean increment observed in
25(OH)D concentration in our study was slightly higher
than that reported by other investigators [28] (0.4 nmol/
L per 100 IU of vitamin D2) it remained lower than that
reported for equimolar doses of vitamin D3 [29-31]. This
could be related to greater potency of vitamin D3 com-
pared to vitamin D2  [32,33] although this has been
recently questioned [34].
Our data must be viewed with appropriate caution. First,
neither PRA nor NT-proBNP was elevated at baseline,
making physiological significance an unresolved issue.
Second, we had no time-matched control women (not
receiving vitamin D) and serum 25(OH)D concentrations
at 2 months remained below the optimal level of 75
nmol/L in all subjects studied. Additionally, pre- and
post-treatment assessments by cardiac echocardiography
were unfortunately not performed as that would have pro-
vided a useful correlate for the NT-proBNP measure-
ments.
Conclusion
We found no significant correlations between 25(OH)D
or PTH with NT-proBNP and PRA in vitamin D deficient
women. There were also no significant correlations
between the change from baseline in 25(OH)D concen-BMC Endocrine Disorders 2009, 9:4 http://www.biomedcentral.com/1472-6823/9/4
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Scatter plot of baseline NT-proBNP in relation to the postpartum day of sample collection Figure 1
Scatter plot of baseline NT-proBNP in relation to the postpartum day of sample collection.
Table 3: Change from baseline in biochemical and clinical variables of lactating women by type of vitamin D supplementation 
regimen1
Variable Daily regimen Monthly regimen Total
Change p value Change p value Change p value2
25OHD (nmol/L) 13.9 ± 2.6 <0.001 10.9 ± 1.8 <0.001 12.3 ± 1.6 <0.001
PTH (pmol/L) 0.1 ± 0.4 0.9 -1.0 ± 0.7 0.2 -0.4 ± 0.4 0.3
Calcium mmol/L -0.09 ± 0.04 0.04 -0.001 ± 0.03 1.0 -0.04 ± 0.02 0.1
NTproBNp (pmol/L) -10.0 ± 3.0 0.003 -8.2 ± 3.0 0.008 -9.1 ± 2.0 <0.001
PRA (nmol/L/hr) -0.4 ± 0.2 0.1 -0.2 ± 0.2 0.4 -0.3 ± 0.2 0.06
SBP (mm Hg) -3.5 ± 2.6 0.2 -0.6 ± 1.8 0.7 -2.0 ± 1.5 0.2
DBP (mm Hg) -4.4 ± 1.4 0.005 1.0 ± 1.9 0.6 -1.6 ± 1.2 0.2
Weight (kg) -0.2 ± 0.6 0.7 -0.4 ± 0.6 0.5 -0.3 ± 0.4 0.5
1 Mean ± SEM;
2 P value by paired two-tailed t-tests.
25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; NT-proBNP, N-terminal pro B-type natriuretic peptide; PRA, plasma rennin activity; 
SBP systolic blood pressure; DBP, diastolic blood pressure.BMC Endocrine Disorders 2009, 9:4 http://www.biomedcentral.com/1472-6823/9/4
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trations or PTH with the change from baseline in NT-
proBNP and PRA levels following vitamin D administra-
tion over a 2-month period. Further information is
required to clarify the effects of vitamin D administration
on cardiac structure and function and prevention of cardi-
ovascular disease.
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